Logo
x

Search

Subscribe Now

p-i

Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC

Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC

  • August 20, 2021
Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar- bevacizumab) for Wet Age-Related Macular Degeneration

Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar- bevacizumab) for Wet Age-Related Macular Degeneration

  • July 19, 2021
Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

  • July 14, 2021
Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors

Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors

  • July 12, 2021
Hutchmed Initiates P-I Trial of HMPL 295 for the Treatment of Advanced Solid Tumors in China

Hutchmed Initiates P-I Trial of HMPL 295 for the Treatment of Advanced Solid Tumors in China

  • July 6, 2021
Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

  • May 27, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.